https://www.prnewswire.com/news-releases/eisai-to-present-full-findings-from-lecanemab-confirmatory-phase-3-clinical-trial-clarity-ad-and-other-alzheimers-disease-research-at-the-15th-clinical-trials-on-alzheimers-disease-ctad-conference-301683436.html
0
0
EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CO - PR Newswire
+ 134 more
11/20/22 at 11:30pm
Organization
PRNewswire
Authors
Details
55 words
Summarize
Neurological Conditions Business & Industrial LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL Eisai Co Ltd Alzheimer's CTAD PRNewswire Haruo Naito Tokyo
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the company's...
Create an account or login to join the discussion